Kenneth S Kendler1, Henrik Ohlsson2, Hermine H Maes3, Kristina Sundquist4, Paul Lichtenstein5, Jan Sundquist4. 1. Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA; Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA; Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA. Electronic address: kendler@vcu.edu. 2. Center for Primary Health Care Research, Lund University, Malmö, Sweden. 3. Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA; Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA. 4. Center for Primary Health Care Research, Lund University, Malmö, Sweden; Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA. 5. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Abstract
BACKGROUND: Prior studies, utilizing interview-based assessments, suggest that most of the genetic risk factors for drug abuse (DA) are non-specific with a minority acting specifically on risk for abuse of particular psychoactive substance classes. We seek to replicate these findings using objective national registry data. METHODS: We examined abuse of cannabis, stimulants (including cocaine) and sedatives ascertained from national Swedish registers in male-male monozygotic (1720 pairs) and dizygotic twins (1219 pairs) combined with near-age full siblings (76,457 pairs) to provide sufficient power. Modeling was performed using Mx. RESULTS: A common pathway model fitted better than an independent pathway model. The latent liability to DA was highly heritable but also influenced by shared environment. Cannabis, stimulant and sedative abuse all loaded strongly on the common factor. Estimates for the total heritability for the three forms of substance abuse ranged from 64 to 70%. Between 75 and 90% of that genetic risk was non-specific, coming from the common factor with the remainder deriving from substance specific genetic risk factors. By contrast, all of the shared environmental effects, which accounted for 18-20% of the variance in liability, were non-specific. CONCLUSIONS: In accord with prior studies based on personal interviews, the large preponderance of genetic risk factors for abuse of specific classes of psychoactive substance are non-specific. These results suggest that genetic variation in the primary sites of action of the psychoactive drugs, which differ widely across most drug classes, play a minor role in human individual differences in risk for DA.
BACKGROUND: Prior studies, utilizing interview-based assessments, suggest that most of the genetic risk factors for drug abuse (DA) are non-specific with a minority acting specifically on risk for abuse of particular psychoactive substance classes. We seek to replicate these findings using objective national registry data. METHODS: We examined abuse of cannabis, stimulants (including cocaine) and sedatives ascertained from national Swedish registers in male-male monozygotic (1720 pairs) and dizygotic twins (1219 pairs) combined with near-age full siblings (76,457 pairs) to provide sufficient power. Modeling was performed using Mx. RESULTS: A common pathway model fitted better than an independent pathway model. The latent liability to DA was highly heritable but also influenced by shared environment. Cannabis, stimulant and sedative abuse all loaded strongly on the common factor. Estimates for the total heritability for the three forms of substance abuse ranged from 64 to 70%. Between 75 and 90% of that genetic risk was non-specific, coming from the common factor with the remainder deriving from substance specific genetic risk factors. By contrast, all of the shared environmental effects, which accounted for 18-20% of the variance in liability, were non-specific. CONCLUSIONS: In accord with prior studies based on personal interviews, the large preponderance of genetic risk factors for abuse of specific classes of psychoactive substance are non-specific. These results suggest that genetic variation in the primary sites of action of the psychoactive drugs, which differ widely across most drug classes, play a minor role in human individual differences in risk for DA.
Authors: Danielle M Dick; Gregory Smith; Peter Olausson; Suzanne H Mitchell; Robert F Leeman; Stephanie S O'Malley; Kenneth Sher Journal: Addict Biol Date: 2010-04 Impact factor: 4.280
Authors: Kenneth S Kendler; Hermine H Maes; Kristina Sundquist; Henrik Ohlsson; Jan Sundquist Journal: Am J Psychiatry Date: 2014-02 Impact factor: 18.112
Authors: M T Lynskey; A C Heath; E C Nelson; K K Bucholz; P A F Madden; W S Slutske; D J Statham; N G Martin Journal: Psychol Med Date: 2002-02 Impact factor: 7.723
Authors: Steven Boker; Michael Neale; Hermine Maes; Michael Wilde; Michael Spiegel; Timothy Brick; Jeffrey Spies; Ryne Estabrook; Sarah Kenny; Timothy Bates; Paras Mehta; John Fox Journal: Psychometrika Date: 2011-04-01 Impact factor: 2.500
Authors: K R Merikangas; M Stolar; D E Stevens; J Goulet; M A Preisig; B Fenton; H Zhang; S S O'Malley; B J Rounsaville Journal: Arch Gen Psychiatry Date: 1998-11
Authors: R Christopher Pierce; Bruno Fant; Sarah E Swinford-Jackson; Elizabeth A Heller; Wade H Berrettini; Mathieu E Wimmer Journal: Neuropsychopharmacology Date: 2018-02-05 Impact factor: 7.853